Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

Abstract Background Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. Methods This study...

Full description

Bibliographic Details
Main Authors: Franziska K. Krebs, Emily R. Trzeciak, Sophia Zimmer, Deniz Özistanbullu, Heidrun Mitzel‐Rink, Markus Meissner, Stephan Grabbe, Carmen Loquai, Andrea Tuettenberg
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Cancer Medicine
Subjects:
checkpoint inhibitor
immunotherapy
malignant melanoma
myeloid‐derived suppressor cells
platelets
Online Access:https://doi.org/10.1002/cam4.3710

Internet

https://doi.org/10.1002/cam4.3710

Similar Items